Trial Profile

An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avacopan (Primary)
Indications IgA nephropathy
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Amgen; ChemoCentryx

Most Recent Events

02 Aug 2023 Last checked against ClinicalTrials.gov record.
31 Jul 2023 Primary endpoints has been amended and trial focus has now shifted to TU and Ar.
19 Feb 2018 This trial has been completed in Sweden, according to European Clinical Trials Database record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com